Compare OGN & SII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OGN | SII |
|---|---|---|
| Founded | 1923 | 2008 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.0B |
| IPO Year | 2020 | 2011 |
| Metric | OGN | SII |
|---|---|---|
| Price | $13.76 | $105.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $11.25 | ★ $135.82 |
| AVG Volume (30 Days) | ★ 2.0M | 86.2K |
| Earning Date | 11-09-2026 | 11-04-2026 |
| Dividend Yield | 0.58% | ★ 1.51% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $6,216,000,000.00 | N/A |
| Revenue This Year | N/A | $35.89 |
| Revenue Next Year | $2.51 | N/A |
| P/E Ratio | ★ $14.48 | $63.42 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.69 | $78.79 |
| 52 Week High | $13.83 | $169.63 |
| Indicator | OGN | SII |
|---|---|---|
| Relative Strength Index (RSI) | 54.03 | 30.71 |
| Support Level | $13.46 | $102.24 |
| Resistance Level | $13.77 | $111.40 |
| Average True Range (ATR) | 0.04 | 3.43 |
| MACD | -0.00 | -0.73 |
| Stochastic Oscillator | 34.78 | 12.50 |
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Sprott Inc is an alternative asset manager. The company has four reportable segments: Exchange Listed Products, which derives key revenue, and includes management services to the company's closed-end physical trusts and exchange-traded funds, both of which are actively traded on public securities exchanges; Managed equities segment provides asset management and sub-advisory services to the company's branded funds, fixed-term LPs and managed accounts; Private strategies which provide lending and streaming activities through limited partnership vehicles; and the Corporate segment which provides capital, balance sheet management and enterprise shared services to the company's subsidiaries. Geographically, it derives key revenue from Canada, followed by the United States.